Erschienen in:
13.05.2019 | ASO Author Reflections
ASO Author Reflections: International Experience of Isolated Limb Infusion for Melanoma Shows Durable Response
verfasst von:
John T. Miura, MD, Hidde M. Kroon, MD, PhD, Jonathan S. Zager, MD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Excerpt
Historically, managing patients with locoregionally metastatic melanoma confined to a limb was challenging due to the paucity of effective treatment options available. Isolated limb perfusion (ILP) and, since its introduction in 1992, isolated limb infusion (ILI) continue to be effective treatment modalities available for such patients. The advantages of ILI over ILP include its minimally invasive approach, lower complexity, and reduced overall morbidity. With the introduction of effective immunotherapy and numerous local (intralesional) therapies, the treatment paradigm for patients with in-transit disease continues to evolve, making it paramount to establish the efficacy of ILI to evaluate its place and relevance in the treatment of locoregionally metastatic limb melanoma. Previous large ILI series have reported favorable overall response rates (ORRs) ranging from 43 to 84%, with complete response (CR) rates ranging from 26 to 38%; however, its effect on long-term oncologic outcomes remains poorly defined.
1,
2 …